About tirofiban
Glycoprotein IIb/IIIa platelet inhibitor
Used for
- Reduces blood clot complications in acute coronary syndrome.
- Used with other medicines during percutaneous coronary intervention.
Usual adult dose
Acute coronary syndrome: 25 micrograms/kg intravenously over 5 minutes, then 0.15 micrograms/kg/minute for up to 18 hours. Dose adjustment is needed with reduced kidney function.
Common side effects
- Bleeding
- Low platelet count
- Nausea
- Fever
Important warnings
- Major bleeding can occur; monitor closely, especially with other blood-thinning medicines.
- Avoid with active bleeding, a history of bleeding disorders, or severe uncontrolled hypertension.
- Kidney impairment requires dose adjustment.
- Platelet counts should be monitored during treatment.
Pregnancy
Limited human data; use only when clearly needed, weighing potential benefits against risks.
Breastfeeding
It is not known whether tirofiban passes into breast milk; breastfeeding decisions require clinical assessment.
Interactions
- Increased bleeding risk with anticoagulants, antiplatelet medicines, and thrombolytics.
- Use with other medicines that affect blood clotting requires close monitoring.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.